Quanterix Reveals Specific Partnership Path For Laboratories Interested In Offering Tau Based Research And Diagnostic Testing Services

3/21/24 5:32:33 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $QTRX alert in real time by email

Those interested in building Alzheimer's disease (AD) testing infrastructure should contact Quanterix to discuss potential partnership opportunities, including avenues for receiving a non-exclusive license to U.S. Patent No. 11,275,092, to measure Tau protein using Quanterix's novel technique.

Get the next $QTRX alert in real time by email

Date	Price Target	Rating	Analyst
2/1/2024	$30.00	Sector Outperform	Scotiabank
9/25/2023	$25.00 → $32.00	Hold → Buy	Canaccord Genuity
8/8/2023	$30.00	Market Perform → Outperform	SVB Securities
5/23/2023	$13.00 → $27.00	Neutral → Buy	Goldman
8/15/2022	$40.00 → $12.00	Buy → Hold	Canaccord Genuity
8/9/2022	$38.00 → $18.00	Outperform → Market Perform	Cowen
8/9/2022	$35.00 → $15.00	Outperform → Mkt Perform	SVB Leerink
3/2/2022	$85.00 → $60.00	Overweight	JP Morgan

Quanterix Reveals Specific Partnership Path For Laboratories Interested In Offering Tau Based Research And Diagnostic Testing Services

Chat with this insight

Recent Analyst Ratings for
$QTRX

Quanterix Reveals Specific Partnership Path For Laboratories Interested In Offering Tau Based Research And Diagnostic Testing Services

Chat with this insight

Recent Analyst Ratings for $QTRX

Recent Analyst Ratings for
$QTRX